These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 29061015)

  • 41. Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders.
    Hsiao SH; Liu HE; Lee HL; Lin CL; Chen WY; Wu ZH; Lin SE; Chiang LL; Chung CL
    PLoS One; 2013; 8(12):e83266. PubMed ID: 24376677
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis: A observational study.
    Wang Y; Wei Y; Ma X; Ma X; Gong P
    Medicine (Baltimore); 2018 Jul; 97(28):e11346. PubMed ID: 29995771
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors.
    Woo HS; Ahn HK; Lee HY; Park I; Kim YS; Hong J; Sym SJ; Park J; Lee JH; Shin DB; Cho EK
    Invest New Drugs; 2014 Dec; 32(6):1311-5. PubMed ID: 25146938
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer.
    Cai L; Zhu JF; Zhang XW; Lin SX; Su XD; Lin P; Chen K; Zhang LJ
    J Neurooncol; 2014 Nov; 120(2):423-30. PubMed ID: 25098700
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer.
    Zhang L; Yang X; Ming Z; Shi J; Lv X; Li W; Yuan B; Chen Y; Liu B; Qin K; Liu J; Wei Q; Gu D; Chen R; Yuan M; Cui J; Ou SI; Yang S
    Clin Lung Cancer; 2022 Jun; 23(4):311-319. PubMed ID: 35045945
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
    Wu JY; Yu CJ; Shih JY
    Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic Impact of Central Nervous System Recurrence After Surgery in Patients With Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer.
    Okamoto T; Takenaka T; Yamazaki K; Hamatake M; Miura N; Takenoyama M; Kometani T; Ueda H; Kouso H; Yano T
    Anticancer Res; 2023 Aug; 43(8):3543-3551. PubMed ID: 37500139
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
    Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
    Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
    Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.
    Pilotto S; Rossi A; Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Spitaleri G; Bria E; Novello S
    Clin Lung Cancer; 2018 Jan; 19(1):93-104. PubMed ID: 28645631
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.
    Kanazu M; Mori M; Kimura M; Nishino K; Shiroyama T; Nagatomo I; Ihara S; Komuta K; Suzuki H; Hirashima T; Kumagai T; Imamura F
    Thorac Cancer; 2021 Jan; 12(1):90-96. PubMed ID: 33124128
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation.
    Huang CH; Ju JS; Chiu TH; Huang AC; Tung PH; Wang CC; Liu CY; Chung FT; Fang YF; Guo YK; Kuo CS; Yang CT
    Int J Cancer; 2022 Feb; 150(4):626-635. PubMed ID: 34558665
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome.
    Kerner GS; Schuuring E; Sietsma J; Hiltermann TJ; Pieterman RM; de Leede GP; van Putten JW; Liesker J; Renkema TE; van Hengel P; Platteel I; Timens W; Groen HJ;
    PLoS One; 2013; 8(7):e70346. PubMed ID: 23922984
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
    Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
    Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer.
    Lin YT; Liu YN; Wu SG; Yang JC; Shih JY
    Clin Lung Cancer; 2017 May; 18(3):324-332.e1. PubMed ID: 28089594
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).
    Janning M; Süptitz J; Albers-Leischner C; Delpy P; Tufman A; Velthaus-Rusik JL; Reck M; Jung A; Kauffmann-Guerrero D; Bonzheim I; Brändlein S; Hummel HD; Wiesweg M; Schildhaus HU; Stratmann JA; Sebastian M; Alt J; Buth J; Esposito I; Berger J; Tögel L; Saalfeld FC; Wermke M; Merkelbach-Bruse S; Hillmer AM; Klauschen F; Bokemeyer C; Buettner R; Wolf J; Loges S;
    Ann Oncol; 2022 Jun; 33(6):602-615. PubMed ID: 35263633
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma.
    Improta G; Zupa A; Natalicchio MI; Sisinni L; Marinaccio A; Bozza G; Vita G; Aieta M; Landriscina M
    Med Oncol; 2018 Jan; 35(3):28. PubMed ID: 29387949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy.
    Hyung J; Yoon H; Choi CM; Yoon S; Lee DH; Kim SW; Kim HR; Kim SS; Song SY; Lee JC
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4243-4251. PubMed ID: 36064984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.